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EXECUTIVE SUMMARY
This document presents guidelines for developing in-
stitutional programs to enhance antimicrobial steward-
ship, an activity that includes appropriate selection,
dosing, route, and duration of antimicrobial therapy.
The multifaceted nature of antimicrobial stewardship
has led to collaborative review and support of these
recommendations by the following organizations:
American Academy of Pediatrics, American Society of
Health-System Pharmacists, Infectious Diseases Society
for Obstetrics and Gynecology, Pediatric Infectious Dis-
eases Society, Society for Hospital Medicine, and Society
of Infectious Diseases Pharmacists. The primary goal
of antimicrobial stewardship is to optimize clinical out-
comes while minimizing unintended consequences of
antimicrobial use, including toxicity, the selection of
pathogenic organisms (such as Clostridium difficile),
and the emergence of resistance. Thus, the appropriate
use of antimicrobials is an essential part of patient safety
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and deserves careful oversight and guidance. Given the
association between antimicrobial use and the selection
of resistant pathogens, the frequency of inappropriate
antimicrobial use is often used as a surrogate marker
for the avoidable impact on antimicrobial resistance.
The combination of effective antimicrobial stewardship
with a comprehensive infection control program has
been shown to limit the emergence and transmission
of antimicrobial-resistant bacteria. A secondary goal of
antimicrobial stewardship is to reduce health care costs
without adversely impacting quality of care.
These guidelines focus on the development of effec-
tive hospital-based stewardship programs and do not
include specific outpatient recommendations. Although
judicious use of antimicrobials is important in out-
patient clinics and long-term care facilities, there are
very few data regarding effective interventions, and it
is unclear which interventions are most responsible for
improvement in these settings.
The population targeted by these guidelines includes
all patients in acute care hospitals. Most of the evidence
supporting the recommendations in these guidelines is
derived from studies of interventions to improve an-
timicrobial use for hospitalized adults. Many of these
studies have focused on adults in intensive care units.
Only a handful of studies have focused on hospitalized
newborns, children, and adolescents. Few studies have
included substantial populations of severely immuno-
compromised patients, such as patients undergoing
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Table 1. Infectious Diseases Society of America–United States Public Health Service grading
system for ranking recommendations in clinical guidelines.
Category, grade Definition
Strength of recommendation
A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation for use
Quality of evidence
I Evidence from 1 properly randomized, controlled trial
II Evidence from 1 well-designed clinical trial, without randomization;
from cohort or case-controlled analytic studies (preferably from 11
center); from multiple time-series; or from dramatic results from
uncontrolled experiments
III Evidence from opinions of respected authorities, based on clinical
experience, descriptive studies, or reports of expert committees
NOTE. Adapted from [1].
hematopoetic stem cell transplantation or receiving chemo-
therapy likely to cause prolonged neutropenia. Nonetheless, the
recommendations in these guidelines are likely to be broadly
applicable to all hospitalized patients.
The ratings of the practices recommended in this document
reflect the likely impact of stewardship practices on improving
antimicrobial use and, consequently, minimizing the emergence
and spread of antimicrobial resistance. Each recommendation
is rated on the basis of the strength of the recommendation
and the quality of evidence supporting it, using the rating sys-
tem of the Infectious Disease Society of America (IDSA), as
shown in table 1 [1]. The ratings provided also reflect the likely
ability of the recommendation to reduce health care costs. Some
strategies to reduce resistance may actually result in an increase
in drug acquisition costs as part of a more comprehensive plan
to reduce overall costs, including the attributable costs of re-
sistance. In situations in which the likely impact of a recom-
mendation on appropriate use of antimicrobials and health care
costs diverge or in which cost data are not available, separate
ratings are given.
Effective antimicrobial stewardship programs can be finan-
cially self-supporting and improve patient care [2–7] (A-II).
Comprehensive programs have consistently demonstrated a de-
crease in antimicrobial use (22%–36%), with annual savings of
$200,000–$900,000 in both larger academic hospitals [2, 3, 5,
7, 8] and smaller community hospitals [4, 6]. Thus, health care
facilities are encouraged to implement antimicrobial steward-
ship programs. A comprehensive evidence-based stewardship
program to combat antimicrobial resistance includes elements
chosen from among the following recommendations based on
local antimicrobial use and resistance problems and on available
resources that may differ, depending on the size of the insti-
tution or clinical setting.
1. Core members of a multidisciplinary antimicrobial ste-
wardship team include an infectious diseases physician and a
clinical pharmacist with infectious diseases training (A-II) who
should be compensated for their time (A-III), with the inclusion
of a clinical microbiologist, an information system specialist,
an infection control professional, and hospital epidemiologist
being optimal (A-III). Because antimicrobial stewardship, an
important component of patient safety, is considered to be a
medical staff function, the program is usually directed by an
infectious diseases physician or codirected by an infectious dis-
eases physician and a clinical pharmacist with infectious dis-
eases training (A-III).
2. Collaboration between the antimicrobial stewardship
team and the hospital infection control and pharmacy and
therapeutics committees or their equivalents is essential (A-III).
3. The support and collaboration of hospital administra-
tion, medical staff leadership, and local providers in the de-
velopment and maintenance of antimicrobial stewardship pro-
grams is essential (A-III). It is desirable that antimicrobial
stewardship programs function under the auspices of quality
assurance and patient safety (A-III).
4. The infectious diseases physician and the head of phar-
macy, as appropriate, should negotiate with hospital admin-
istration to obtain adequate authority, compensation, and ex-
pected outcomes for the program (A-III).
5. Hospital administrative support for the necessary in-
frastructure to measure antimicrobial use and to track use on
an ongoing basis is essential (A-III).
6. There are 2 core strategies, both proactive, that provide
the foundation for an antimicrobial stewardship program.
These strategies are not mutually exclusive.
A. Prospective audit with intervention and feedback.
Prospective audit of antimicrobial use with direct interaction
and feedback to the prescriber, performed by either an infec-
tious diseases physician or a clinical pharmacist with infectious
diseases training, can result in reduced inappropriate use of
antimicrobials (A-I).
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B. Formulary restriction and preauthorization. For-
mulary restriction and preauthorization requirements can lead
to immediate and significant reductions in antimicrobial use
and cost (A-II) and may be beneficial as part of a multifaceted
response to a nosocomial outbreak of infection (B-II). The use
of preauthorization requirements as a means of controlling
antimicrobial resistance is less clear, because a long-term ben-
eficial impact on resistance has not been established, and in
some circumstances, use may simply shift to an alternative
agent with resulting increased resistance (B-II). In institutions
that use preauthorization to limit the use of selected antimi-
crobials, monitoring overall trends in antimicrobial use is nec-
essary to assess and respond to such shifts in use (B-III).
7. The following elements may be considered and pri-
oritized as supplements to the core active antimicrobial ste-
wardship strategies based on local practice patterns and re-
sources.
A. Education. Education is considered to be an es-
sential element of any program designed to influence prescrib-
ing behavior and can provide a foundation of knowledge that
will enhance and increase the acceptance of stewardship strat-
egies (A-III). However, education alone, without incorporation
of active intervention, is only marginally effective in changing
antimicrobial prescribing practices and has not demonstrated
a sustained impact (B-II).
B. Guidelines and clinical pathways. Multidisci-
plinary development of evidence-based practice guidelines
incorporating local microbiology and resistance patterns can
improve antimicrobial utilization (A-I). Guideline implemen-
tation can be facilitated through provider education and feed-
back on antimicrobial use and patient outcomes (A-III).
C. Antimicrobial cycling. There are insufficient data
to recommend the routine use of antimicrobial cycling as a
means of preventing or reducing antimicrobial resistance over
a prolonged period of time (C-II). Substituting one antimi-
crobial for another may transiently decrease selection pressure
and reduce resistance to the restricted agent. Unless the resis-
tance determinant has been eliminated from the bacterial pop-
ulation, however, reintroduction of the original antimicrobial
is again likely to select for the expression of the resistance
determinant in the exposed bacterial population.
D. Antimicrobial order forms. Antimicrobial order
forms can be an effective component of antimicrobial ste-
wardship (B-II) and can facilitate implementation of practice
guidelines.
E. Combination therapy. There are insufficient data
to recommend the routine use of combination therapy to pre-
vent the emergence of resistance (C-II). Combination therapy
does have a role in certain clinical contexts, including use for
empirical therapy for critically ill patients at risk of infection
with multidrug-resistant pathogens, to increase the breadth of
coverage and the likelihood of adequate initial therapy (A-II).
F. Streamlining or de-escalation of therapy. Stream-
lining or de-escalation of empirical antimicrobial therapy on
the basis of culture results and elimination of redundant com-
bination therapy can more effectively target the causative path-
ogen, resulting in decreased antimicrobial exposure and sub-
stantial cost savings (A-II).
G. Dose optimization. Optimization of antimicrobial
dosing based on individual patient characteristics, causative or-
ganism, site of infection, and pharmacokinetic and pharma-
codynamic characteristics of the drug is an important part of
antimicrobial stewardship (A-II).
H. Parenteral to oral conversion. A systematic plan
for parenteral to oral conversion of antimicrobials with excel-
lent bioavailability, when the patient’s condition allows, can
decrease the length of hospital stay and health care costs (A-
I). Development of clinical criteria and guidelines allowing
switch to use of oral agents can facilitate implementation at
the institutional level (A-III).
8. Health care information technology in the form of elec-
tronic medical records (A-III), computer physician order entry
(B-II), and clinical decision support (B-II) can improve anti-
microbial decisions through the incorporation of data on pa-
tient-specific microbiology cultures and susceptibilities, hepatic
and renal function, drug-drug interactions, allergies, and cost.
However, implementation of these features has been slow, and
conformation of the technology to the clinical environment
remains a challenge.
9. Computer-based surveillance can facilitate good ste-
wardship by more efficient targeting of antimicrobial interven-
tions, tracking of antimicrobial resistance patterns, and iden-
tification of nosocomial infections and adverse drug events
(B-II).
10. The clinical microbiology laboratory plays a critical
role in antimicrobial stewardship by providing patient-specific
culture and susceptibility data to optimize individual antimi-
crobial management and by assisting infection control efforts
in the surveillance of resistant organisms and in the molecular
epidemiologic investigation of outbreaks (A-III).
11. Both process measures (did the intervention result in
the desired change in antimicrobial use?) and outcome mea-
sures (did the process implemented reduce or prevent resistance
or other unintended consequences of antimicrobial use?) are
useful in determining the impact of antimicrobial stewardship
on antimicrobial use and resistance patterns (B-III).
INTRODUCTION
Purpose. In recognition that antimicrobial resistance results
in increased morbidity, mortality, and cost of health care, the
IDSA initially published guidelines for improving the use of
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Table 2. Causal associations between antimicrobial use and
the emergence of antimicrobial resistance.
Changes in antimicrobial use are paralleled by changes in the
prevalence of resistance.
Antimicrobial resistance is more prevalent in health
care–associated bacterial infections, compared with those from
community-acquired infections.
Patients with health care–associated infections caused by resis-
tant strains are more likely than control patients to have re-
ceived prior antimicrobials.
Areas within hospitals that have the highest rates of antimicrobial
resistance also have the highest rates of antimicrobial use.
Increasing duration of patient exposure to antimicrobials increases
the likelihood of colonization with resistant organisms.
NOTE. A causal association between antimicrobial use and the emergence
of antimicrobial resistance has been reviewed elsewhere [9, 19–22] and is
strongly suggested on the basis of several lines of evidence that are derived
from patient and population levels of analysis, colonization and infection data,
and retrospective and prospective studies [23–31]. Adapted from [10].
antimicrobial agents in hospitals in 1988 [9] and then jointly
published guidelines with the Society for Healthcare Epide-
miology of America in 1997 for the prevention of antimicrobial
resistance in hospitals [10]. However, subsequent surveys of
hospitals have found that practices to improve antimicrobial
use are frequently inadequate and not routinely implemented
[11–13]. The purpose of these guidelines is to build on the
previous position statements, as well as to provide evidence-
based recommendations for developing a program to enhance
antimicrobial stewardship in the hospital setting to improve
the quality of care. These guidelines are not a substitute for
clinical judgment, and clinical discretion is required in the ap-
plication of guidelines to individual patients.
Effective antimicrobial stewardship programs, also known as
antimicrobial management programs, can be financially self-
supporting and can improve patient care [2–7] (A-II). Anti-
microbial stewardship includes not only limiting inappropriate
use but also optimizing antimicrobial selection, dosing, route,
and duration of therapy to maximize clinical cure or prevention
of infection while limiting the unintended consequences, such
as the emergence of resistance, adverse drug events, and cost.
Given the emergence of multidrug-resistant pathogens and
their impact on clinical care, appropriate use of antimicrobial
agents has become a focus of patient safety and quality assur-
ance along with medication errors, allergy identification, and
drug-drug interactions [14]. The ultimate goal of antimicrobial
stewardship is to improve patient care and health care
outcomes.
From the institutional perspective, antimicrobials account
for upwards of 30% of hospital pharmacy budgets [15]. It has
been recognized for several decades that up to 50% of anti-
microbial use is inappropriate, adding considerable cost to pa-
tient care [8, 9, 15–18]. In addition to direct pharmacy ac-
quisition costs, numerous reports suggest that inappropriate
and unnecessary antimicrobial use leads to increased selection
of resistant pathogens (table 2). Once antimicrobial resistance
emerges, it can have a significant impact on patient morbidity
and mortality, as well as increased health care costs [32, 33].
Bacteremia [34, 35] and surgical site infections [36] due to
methicillin-resistant Staphylococcus aureus (MRSA) have been
associated with a higher mortality rate than similar infections
due to methicillin-susceptible S. aureus, with the mean attrib-
utable cost of an MRSA infection ranging from $9275 to
$13,901 [36, 37]. Similarly, compared with vancomycin-sus-
ceptible Enterococcus faecium infections, bloodstream infections
due to vancomycin-resistant E. faecium (VRE) were associated
with decreased survival (24% vs. 59%), increased length of
hospital stay (34.8 vs. 16.7 days), and an attributable cost of
$27,190 per episode [38, 39]. A meta-analysis of 9 studies of
VRE bloodstream infections found an attributable excess mor-
tality of 30%, compared with vancomycin-susceptible Entero-
coccus bloodstream infections [40]. Similar adverse outcomes
have also been reported for infections with resistant gram-
negative organisms, including Pseudomonas, Acinetobacter, and
Enterobacter species and extended-spectrum b-lactamase–
producing organisms [41]. A case-control study found that
third-generation cephalosporin–resistant Enterobacter infec-
tions were associated with increased mortality (relative risk,
5.02), length of hospital stay (1.5-fold increase), and an attrib-
utable cost of $29,379 [42]. The emergence of infections with
multidrug-resistant gram-negative organisms, combined with
a paucity of new drug development, has unfortunately led to
the resurgent use of colistin, a polymyxin antimicrobial pre-
viously abandoned because of its high rates of nephrotoxicity
and neurotoxicity [43]. In 1998, the Institute of Medicine es-
timated that the annual cost of infections caused by antimi-
crobial-resistant bacteria was $4–$5 billion [44].
Methods. The recommendations in this guideline are based
on a review of published studies identified through a search of
the PubMed database (search terms used alone and in com-
bination included “antimicrobial,” “antibiotic,” “stewardship,”
“management,” “resistance,” “cost,” “education,” “guidelines,”
“restriction,” “cycling,” “order forms,” and “combination ther-
apy”) supplemented by review of references of relevant articles
to identify additional reports. Committee members were also
asked to cite additional relevant studies to support the rec-
ommendations. Because of the limited number of randomized,
controlled trials, results from prospective cohort studies, case-
control studies, longitudinal time series, and other descriptive
studies are included in the review. The ratings of the practices
recommended in this document reflect the likely impact of such
practices on improving antimicrobial use and, ultimately, an-
timicrobial resistance. Given the association between antimi-
crobial use and the selection of resistant pathogens, rates of
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inappropriate antimicrobial use are considered as surrogate
markers for the avoidable impact on antimicrobial resistance.
The strength of the recommendations and quality of evidence
are rated using IDSA criteria (table 1) [1]. Individual studies
were evaluated both for their impact on the targeted antimi-
crobial(s) or resistance problem and for any secondary impact
on local antimicrobial use and resistance patterns. The ratings
also reflect the likely ability of the recommendation to reduce
health care costs. In situations in which the likely impact of a
recommendation on appropriate use of antimicrobials and
health care costs diverge or cost data are not available, separate
ratings are given. Recommendations reflect a compilation of
the studies in each section, as well as the opinions of the com-
mittee members.
GUIDELINES FOR DEVELOPING AN
INSTITUTIONAL PROGRAM TO ENHANCE
ANTIMICROBIAL STEWARDSHIP
THE ANTIMICROBIAL STEWARDSHIP TEAM
AND ADMINISTRATIVE SUPPORT
It is essential that the antimicrobial stewardship team includes
an infectious diseases physician and a clinical pharmacist with
infectious diseases training and that both of these individuals
are compensated appropriately for their time. Optimally, the
team should include a clinical microbiologist who can provide
surveillance data on antimicrobial resistance, as well as an in-
formation system specialist who can provide the computer sup-
port necessary for surveillance and implementation of rec-
ommendations. In addition, it is optimal that the team includes
an infection control professional and hospital epidemiologist
to coordinate efforts on improving antimicrobial use, because
reduction of antimicrobial resistance is a common goal of these
persons. Because antimicrobial stewardship, an important com-
ponent of patient safety, is considered to be a medical staff
function, the program is usually directed by an infectious dis-
eases physician or codirected by an infectious diseases physician
and a clinical pharmacist with infectious diseases training. The
clinical pharmacist should be knowledgeable on the appropriate
use of antimicrobials, and appropriate training should be made
available to achieve and maintain this expertise. It is essential
that there be support and collaboration between the antimi-
crobial stewardship team and the hospital infection control and
pharmacy and therapeutics committees or their equivalents.
The support and collaboration of hospital administration,
medical staff leadership, and local providers in the development
and maintenance of antimicrobial stewardship programs is es-
sential to success of the program. In this regard, the infectious
diseases physician and the head of pharmacy, as appropriate,
should negotiate with hospital administration to obtain ade-
quate authority, compensation, and expected outcomes for the
program (A-III). It is essential that there be hospital admin-
istrative support for the necessary infrastructure, to measure
antimicrobial use and to track use on an ongoing basis (A-III).
It is desirable that antimicrobial stewardship programs function
under the auspices of quality assurance and patient safety. Prior
to program implementation, the antimicrobial stewardship
strategic plan should be presented to and approved by the chiefs
of professional services, hospital medical staff executive com-
mittee, and/or other medical staff governing bodies, to ensure
their acceptance and support.
Recommendations
• Core members of a multidisciplinary antimicrobial ste-
wardship team include an infectious diseases physician and
a clinical pharmacist with infectious diseases training (A-
II) who should be compensated for their time (A-III), with
the inclusion of a clinical microbiologist, an information
system specialist, an infection control professional, and hos-
pital epidemiologist being optimal (A-III). Because anti-
microbial stewardship, an important component of patient
safety, is considered to be a medical staff function, the pro-
gram is usually directed by an infectious diseases physician
or codirected by an infectious diseases physician and a clin-
ical pharmacist with infectious diseases training (A-III).
• Collaboration between the antimicrobial stewardship team
and the hospital infection control and pharmacy and ther-
apeutics committees, or their equivalents, is essential (A-
III).
• The support and collaboration of hospital administration,
medical staff leadership, and local providers in the devel-
opment and maintenance of antimicrobial stewardship pro-
grams is essential (A-III). It is desirable that antimicrobial
stewardship programs function under the auspices of quality
assurance and patient safety (A-III).
• The infectious diseases physician and the head of pharmacy,
as appropriate, should negotiate with hospital administra-
tion to obtain adequate authority, compensation, and ex-
pected outcomes for the program (A-III).
• Hospital administrative support for the necessary infrastruc-
ture to measure antimicrobial use and to track use on an
ongoing basis is essential (A-III).
ELEMENTS OF AN ANTIMICROBIAL
STEWARDSHIP PROGRAM
The best strategies for the prevention and containment of an-
timicrobial resistance are not definitively established, because
there is a paucity of randomized, controlled trials in this field
[45]. Often, multiple interventions have been made simulta-
neously, making it difficult to assess the benefit attributable to
any one specific intervention. However, a comprehensive pro-
gram that includes active monitoring of resistance, fostering of
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appropriate antimicrobial use, and collaboration with an ef-
fective infection control program to minimize secondary spread
of resistance [46, 47] is considered to be optimal [48]. A com-
prehensive evidence-based stewardship program to combat an-
timicrobial resistance includes elements chosen from among
the following strategies, which are based on local antimicrobial
use and resistance problems, and on available resources that
may differ depending on the size of the institution or clinical
setting.
Active Antimicrobial Stewardship Strategies
Prospective audit with intervention and feedback. Pro-
spective audit of antimicrobial use with intervention and feed-
back to the prescriber have been demonstrated to improve
antimicrobial use. In a large teaching hospital, house staff were
randomized by the medical service to receive either no inter-
vention or one-on-one education by a clinical specialist (aca-
demic detailing) on a patient-specific basis, emphasizing mi-
crobiologic data, local resistance patterns, and clinical literature,
when the pharmacy received an order for either levofloxacin
or ceftazidime. This resulted in a 37% reduction in the number
of days of unnecessary levofloxacin or ceftazidime use by de-
creasing the duration of therapy, as well as reducing new starts,
suggesting that house staff learned not to initiate unnecessary
antibiotic treatment regimens [49]. At a 600-bed tertiary teach-
ing hospital, inpatients receiving parenteral antimicrobials cho-
sen by their primary care physician were randomized to an
intervention group that received antimicrobial-related sugges-
tions from an infectious diseases fellow and a clinical phar-
macist versus no antimicrobial suggestions. Physicians in the
intervention group received 74 suggestions for 62 of 127 pa-
tients, including suggestions on a more appropriate agent, route
of administration, dosing, discontinuation of the drug, or tox-
icity monitoring. Eighty-five percent of the suggestions were
implemented, resulting in 1.6 fewer days of parenteral therapy
and a cost savings of $400 per patient, with no adverse impact
on clinical response, compared with the control group [50].
There was a trend, however, toward increasing rates of read-
mission in the intervention group, emphasizing the need to
monitor the impact of such interventions designed to decrease
length of hospital stay.
Prospective audit and interventions by a clinical pharmacist
and infectious diseases physician at a medium-sized community
hospital resulted in a 22% decrease in the use of parenteral
broad-spectrum antimicrobials, despite a 15% increase in pa-
tient acuity over a 7-year period [3]. They also demonstrated
a decrease in rates of C. difficile infection and nosocomial in-
fection caused by drug-resistant Enterobacteriaceae, compared
with the preintervention period.
In hospitals where daily review of antimicrobial use is not
feasible because of limited resources, a scaled-down model can
still have a significant impact, as illustrated by a small, 120-
bed community hospital that used an infectious diseases phy-
sician and clinical pharmacist 3 days per week to review patients
receiving multiple, prolonged, or high-cost courses of anti-
microbial therapy [4]. Sixty-nine percent of 488 recommen-
dations were implemented, resulting in a 19% reduction in
antimicrobial expenditures for an estimated annual savings of
$177,000, compared with the preintervention period. In these
studies, interventions were communicated to prescribers either
verbally or in writing. Written communication was typically
accomplished by using special, nonpermanent forms that were
placed in the medical record or chart but were subsequently
removed after the intervention or at the time of discharge from
the hospital. Each intervention provides the opportunity for
provider education.
Effective audit with intervention and feedback can be facil-
itated through computer surveillance of antimicrobial use, al-
lowing the targeting of specific services or units where problems
exist, as well as identification of patients receiving particular
agents or combinations of agents that might benefit from
intervention.
Recommendation
• Prospective audit of antimicrobial use with direct interac-
tion and feedback to the prescriber, performed by either an
infectious diseases physician or a clinical pharmacist with
infectious diseases training, can result in reduced inappro-
priate use of antimicrobials (A-I).
Formulary restriction and preauthorization requirements
for specific agents. Most hospitals have a pharmacy and ther-
apeutics committee or an equivalent group that evaluates drugs
for inclusion on the hospital formulary on the basis of con-
siderations of therapeutic efficacy, toxicity, and cost while lim-
iting redundant new agents with no significant additional ben-
efit. Antimicrobial restriction—either through formulary
limitation by this method or by the requirement of preau-
thorization and justification—is the most effective method of
achieving the process goal of controlling antimicrobial use.
Longitudinal studies implementing restrictive policies have
demonstrated significant initial decreases in the use of the tar-
geted antimicrobials, with annual antimicrobial cost savings
ranging upwards of $800,000 [14, 51–57]. The achievement of
the outcome goal of reducing antimicrobial resistance has not
been as clear, as illustrated by the following studies.
Both formulary restriction [58] and preauthorization re-
quirements for use of clindamycin [59] during nosocomial ep-
idemics of C. difficile infection have led to prompt cessation of
the outbreaks, whereas preapproval restriction of broad-
spectrum antimicrobials has led to short-term increased sus-
ceptibilities among gram-negative pathogens, such as Pseudo-
monas aeruginosa, Klebsiella pneumoniae, and Enterobacter
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cloacae, during a 6–12-month period [57, 60]. Restriction of
vancomycin and third-generation cephalosporins in response
to increasing rates of VRE has demonstrated mixed results [61–
63]. Fecal VRE colonization rates of 47% (despite barrier pre-
cautions) led one center to restrict vancomycin and cefotaxime
use while encouraging the replacement of third-generation
cephalosporins with b-lactam/b-lactamase inhibitor combina-
tions. This led to a reduction in the rates of monthly use of
vancomycin, cefotaxime, and ceftazidime by 34%, 84%, and
55%, respectively, and rates of ampicillin-sulbactam and
piperacillin-tazobactam use increased. This was accompanied
by a decrease in the fecal VRE point prevalence from 47% to
15% during 6 months [59]. In contrast, in another study, the
prevalence of VRE increased from 17% to 30%, despite the
restriction on the use of vancomycin and third-generation
cephalosporins during a 10-year period [64]. The interpretation
of these study results is often confounded by concomitant
changes in infection control practices and by the influence of
nonrestricted antimicrobial agents on gut flora.
Studies of antibiotic-restriction policies among pediatric pa-
tients have demonstrated inconsistent results. A crossover study
of 2 neonatal intensive care units (ICUs) compared 2 ap-
proaches for empirical treatment of early- and late-onset sus-
pected sepsis—a “broad-spectrum” regimen consisting of am-
picillin and cefotaxime versus a “narrow-spectrum” regimen
consisting of penicillin and tobramycin—on the prevalence of
colonization with bacteria resistant to each of the regimens [65].
The narrow-spectrum regimen was associated with a markedly
lower prevalence of colonization with resistant gram-negative
bacilli. In contrast, a quasi experimental study from a pediatric
ICU of a policy to restrict ceftazidime use (piperacillin-
tazobactam was the preferred regimen) found no change in the
incidence of colonization with ceftazidime-resistant gram-
negative bacilli, although there was a decrease in the prevalence
of colonization with specific species of gram-negative bacilli
that commonly harbor inducible AmpC b-lactamases (e.g., E.
cloacae, Serratia marcesens, Citrobacter freundii, and P. aerugi-
nosa) [66].
The effectiveness of a preauthorization program depends on
who is making the recommendations. Restriction of cefotaxime
use through a program requiring approval from a chief resident
or attending physician had no impact on its use [67]. Rec-
ommendations from an antimicrobial management team con-
sisting of a pharmacist and an infectious diseases physician
resulted in increased antimicrobial appropriateness, increased
clinical cure, and a trend towards improved economic outcome,
compared with recommendations made by infectious diseases
fellows [68].
The challenge of antimicrobial restriction and its effect on
antimicrobial resistance is exemplified in a study by Rahal et
al. [27]. In response to an increasing incidence of cephalospo-
rin-resistant Klebsiella, a preapproval policy was implemented
for cephalosporins. This resulted in an 80% reduction in hos-
pital-wide cephalosporin use and a subsequent 44% reduction
in the incidence of ceftazidime-resistant Klebsiella throughout
the medical center, as well as a 71% reduction in the ICUs.
Concomitantly, however, imipenem use increased 141%, ac-
companied by a 69% increase in the incidence of imipenem-
resistant P. aeruginosa. This untoward restrictive effect of
“squeezing the balloon” may counteract the originally sought
benefits [69]. Furthermore, restricting use of a single drug to
prevent or reverse antimicrobial resistance may be ineffective,
because multiple antimicrobials may be associated with changes
in susceptibility to other drugs for a given pathogen [70].
Recommendation
• Formulary restriction and preauthorization requirements
can lead to immediate and significant reductions in anti-
microbial use and cost (A-II) and may be beneficial as part
of a multifaceted response to a nosocomial outbreak of
infection (B-II). The use of preauthorization requirements
as a means of controlling antimicrobial resistance is less
clear, because a long-term beneficial impact on resistance
has not been established, and in some circumstances, use
may simply shift to an alternative agent with resulting in-
creased resistance (B-II). In institutions that use preau-
thorization to limit the use of selected antimicrobials, mon-
itoring overall trends in antimicrobial use is necessary to
assess and respond to such shifts in use (B-III).
Supplemental Antimicrobial Stewardship Strategies
Education. Education is the most frequently employed in-
tervention and is considered to be an essential element of any
program designed to influence prescribing behavior. Educa-
tional efforts include passive activities, such as conference pre-
sentations, student and house staff teaching sessions, and pro-
vision of written guidelines or e-mail alerts. However, education
alone, without incorporation of active intervention, is only
marginally effective and has not demonstrated a sustained im-
pact [71–73].
Step-wise implementation of an antimicrobial stewardship
program initially with passive strategies, such as education and
order forms, followed by an active strategy with prospective audit
and intervention demonstrated progressive decreases in anti-
microbial consumption, resulting in a savings of $913,236 over
18 months. During the period of active intervention, 25% of
antimicrobial orders were modified (86% resulted in less expen-
sive therapy, and 47% resulted in use of a drug with a narrower
spectrum of activity), resulting in a significant increase in mi-
crobiologically based prescribing (63% vs. 27%) [71].
In an attempt to improve adherence to recommendations
for perioperative antimicrobial prophylaxis, a before-and-after
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study compared prescribing practices after distribution of an
educational handbook with those after the introduction of an
order form. The educational handbook led to a marginal im-
provement in compliance (from 11% to 18%), whereas intro-
duction of the order form led to significantly improved com-
pliance (from 17% to 78%) [73].
Recommendation
• Education is considered to be an essential element of any
program designed to influence prescribing behavior and can
provide a foundation of knowledge that will enhance and
increase the acceptance of stewardship strategies (A-III).
However, education alone, without incorporation of active
intervention, is only marginally effective in changing anti-
microbial prescribing practices and has not demonstrated a
sustained impact (B-II).
Guidelines and clinical pathways. Clinical practice guide-
lines are being produced with increasing frequency, with the
goal of ensuring high-quality care. However, the impact on
provider behavior and improved clinical outcomes has been
difficult to measure. Although physicians usually agree, in prin-
ciple, with national guidelines, the absence of accompanying
strategies for local implementation often presents a formidable
barrier [74]. Antimicrobial stewardship programs can facilitate
multidisciplinary development of evidence-based practice
guidelines that incorporate local microbiology and resistance
patterns.
Randomized implementation of a clinical pathway, com-
pared with conventional management of community-acquired
pneumonia, among 20 hospitals led to a 1.7-day decrease in
the median length of hospital stay, an 18% decrease in the rate
of admissions of low-risk patients, and 1.7 fewer mean days of
intravenous therapy in the intervention group, without an in-
crease in complications, readmissions, or mortality [75]. In
another study, multidisciplinary development of practice guide-
lines based on evidence in the literature and local microbiology
and resistance patterns and implementation in a surgical ICU
led to a 77% reduction in antimicrobial use and cost, a 30%
reduction in overall cost of care, decreased mortality among
patients with infection, and a trend towards reduced length of
ICU stay, compared with the preimplementation time period
[76]. Importantly, both of these studies demonstrate that an-
timicrobial selection is only 1 component in improving the
management of infectious diseases and cannot be done without
recommendations for diagnosis and testing, admission criteria,
nursing care, conversion to oral medication, and discharge
planning. Whether the use of guidelines will lead to a long-
term impact on antimicrobial resistance remains to be deter-
mined, but the following studies of hospital-acquired pneu-
monia (HAP) and ventilator-associated pneumonia (VAP)
suggest that improving antimicrobial use through the use of
guidelines may decrease the emergence of resistant pathogens.
The increasing incidence of multidrug-resistant organisms
in cases of HAP and VAP, the diagnostic challenge of these
entities, and the mortality benefit associated with initial ap-
propriate therapy [77] have led to an increased use of broad-
spectrum antimicrobials, which must be balanced against fur-
ther selection of resistant pathogens. Invasive diagnosis of VAP
with quantitative bronchoscopy for diagnosis and antimicrobial
guidance led to reduced mortality at 14 days and a decrease in
antimicrobial use [78]. Another strategy to address the inap-
propriate use of antimicrobials in the ICU setting used an al-
gorithm incorporating the clinical pulmonary infection score
to identify patients with a low likelihood of pneumonia. Pa-
tients randomized to the intervention group who continued to
have a low clinical pulmonary infection score (6) had their
antimicrobial therapy discontinued at day 3, and the control
group received the standard 10–21 days of therapy. This led to
a significant decrease in duration of therapy (3 vs. 9.8 days)
and antimicrobial cost ($400 per patient), with no difference
in mortality. In addition, the development of antimicrobial
resistance and/or superinfections was less common in the group
receiving the short-course antimicrobial therapy (15% vs. 35%)
[79]. A prospective before-and-after study of a clinical guideline
for the management of VAP incorporated broad empirical ther-
apy based on local microbiology with culture-driven de-esca-
lation and a standard 7-day course of therapy. Implementation
of the protocol led to increased initial administration of ade-
quate antimicrobial therapy (94% vs. 48%), decreased duration
of therapy (8.6 vs. 14.8 days), and decreased VAP recurrence
(8% vs. 24%), without affecting patient mortality [80]. The
efficacy of short-course therapy for VAP was subsequently con-
firmed in a randomized study of 8 versus 15 days of antimi-
crobial therapy in patients with VAP documented by quanti-
tative culture of samples obtained by bronchoscopy. There was
no difference in mortality or recurrent infection in patients
who received the shorter course of therapy, but the short-course
group did have more antimicrobial-free days (13.1 vs. 8.7) and
a decreased rate of emergence of multidrug-resistant pathogens
among those patients with recurrences of pulmonary infection
(42% vs. 62%) [81]. These studies support the development
and implementation of evidence-based guidelines for diagnosis
and antimicrobial therapy for HAP and VAP.
A quasi experimental study in a pediatric hospital in Australia
demonstrated similar results regarding the use of guidelines to
improve therapy for common infections [82]. The investigators
provided recommendations for the treatment of childhood in-
fections on a laminated card that could be clipped to a hospital
badge. When the 6-month period during implementation of
the intervention (intervention period) was compared with the
prior 6 months (baseline period), the intervention was asso-
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ciated with substantial increases in the percentage of prescrip-
tions with the correct choice and dose of antimicrobial agents
for 2 of 3 indicator infections (pneumonia and orbital/perior-
bital cellulitis). The cost of third-generation cephalosporins was
reduced by more than one-half in the intervention period.
Recommendation
• Multidisciplinary development of evidence-based practice
guidelines incorporating local microbiology and resistance
patterns can improve antimicrobial utilization (A-I). Guide-
line implementation can be facilitated through provider ed-
ucation and feedback on antimicrobial use and patient out-
comes (A-III).
Antimicrobial cycling and scheduled antimicrobial switch.
“Antimicrobial cycling” refers to the scheduled removal and
substitution of a specific antimicrobial or antimicrobial class
to prevent or reverse the development of antimicrobial resis-
tance within an institution or specific unit. In true cycling,
there is a return to the original antimicrobial after a defined
time, as opposed to a simple switch of antimicrobials [83–86].
In many respects, cycling is an attempt at controlled hetero-
geneity of antimicrobial use to minimize antimicrobial selection
pressures. Studies of true antimicrobial cycling are limited and
vary in terms of antimicrobial class selection, duration of cy-
cling, therapeutic options offered during cycling periods, and
cycling by time period versus by patient. Concerns about al-
lergies, adverse drug events, and conflicts with national guide-
lines have led to 10%–50% of patients in cycling programs to
receive “off-cycle” antimicrobials, resulting in poor implemen-
tation of the intended process change, with multiple antimi-
crobials being used at the same time by different patients [85].
Driven by both increasing resistance among Enterobacteri-
aceae and pricing changes, the largest cycling experience has
been reported for changes in aminoglycoside use—particularly,
substituting amikacin for gentamicin. Such a switch in ami-
noglycoside use has been associated with a significant reduction
in gentamicin resistance [87–93]; however, rapid reintroduction
of gentamicin was accompanied by a rapid return of gentamicin
resistance [89, 92]. In one institution with 10 years of expe-
rience, this led to an additional cycle of amikacin followed by
a more gradual return of gentamicin, without an associated
increase in resistance once the original gentamicin resistance
plasmids could no longer be detected [92]. This last example
highlights the importance of understanding and monitoring
mechanisms of resistance over the long term when developing
protocols for antimicrobial cycling. Once antimicrobial resis-
tance emerges, it will often persist even in the absence of direct
antimicrobial selection pressure, potentially minimizing the im-
pact of antimicrobial removal strategies [21].
A switch from the empirical use of ceftazidime to cipro-
floxacin for suspected gram-negative bacterial infection in a
cardiothoracic ICU led to a decreased incidence of VAP due
to multidrug-resistant, gram-negative bacteria (1% vs. 4%)
[94]. Restriction of ceftazidime and ciprofloxacin in a medical
ICU, combined with cycling of the preferred b-lactam agent at
monthly intervals, led to a decreased incidence of VAP and
improved susceptibilities for P. aeruginosa. Because these ma-
neuvers, as well as de-escalation of therapy based on culture
results, led to a 50% reduction in overall antimicrobial use, the
benefit of cycling alone cannot be ascertained [95]. Quarterly
rotation of empirical antimicrobial regimens in a surgical ICU
for pneumonia and peritonitis/sepsis led to a decreased inci-
dence of resistant bacterial infections and mortality due to in-
fection [96]. However, significant patient population differ-
ences and the simultaneous changes in infection control,
including institution of an antibiotic surveillance team and the
introduction of alcohol gel dispensers, confounded interpre-
tation of the results. In addition, only 62%–83% of patients
received the “on-cycle” antimicrobial intended in the process
change, resulting in antimicrobial mixing as opposed to time
period–based cycling.
It should be noted that mathematical modeling suggests that
true cycling is unlikely to reduce the evolution or spread of
antimicrobial resistance. Rather, such modeling suggests that
the simultaneous mixed use of different antimicrobial classes
in a heterogeneous fashion may slow the spread of resistance
[97, 98].
In an attempt to examine this hypothesis, a prospective cross-
over study compared the effects of monthly cycling of antip-
seudomonal agents (cefepime or ceftazidime, ciprofloxacin, im-
ipenem or meropenem, or piperacillin-tazobactam) with the
use of these agents in the same order by consecutive patients
(i.e., mixing) [99]. During mixing, a significantly higher pro-
portion of patients acquired a strain of P. aeruginosa that was
resistant to cefepime (9% vs. 3%; ). As in previousP p .01
cycling studies, however, adherence to the cycling regimen was
problematic, with scheduled antimicrobials never accounting
for more than 45% of all antipseudomonal antimicrobials. Ad-
ditional clinical studies to examine optimal cycling parameters
and the role of antimicrobial diversity are needed.
Recommendation
• There are insufficient data to recommend the routine use
of antimicrobial cycling as a means of preventing or re-
ducing antimicrobial resistance over a prolonged period of
time (C-II). Substituting one antimicrobial for another may
transiently decrease selection pressure and reduce resistance
to the restricted agent. Unless the resistance determinant
has been eliminated from the bacterial population, however,
reintroduction of the original antimicrobial is again likely
to select for the expression of the resistance determinant in
the exposed bacterial population.
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Antimicrobial order forms. Antimicrobial order forms de-
crease antimicrobial consumption in longitudinal studies
through the use of automatic stop orders and the requirement
of physician justification [100, 101]. Prior to more recent
studies further defining the optimal timing and duration of
perioperative antimicrobial prophylaxis [102, 103], use of per-
ioperative prophylactic order forms with automatic discon-
tinuation at 2 days resulted in a decrease in the mean duration
of antimicrobial prophylaxis (from 4.9 to 2.4 days) and a
decrease in the percentage of patients receiving perioperative
prophylaxis for 12 days (from 85% to 44%) [100]. The rate
of inappropriate initiation of antimicrobial prophylaxis post-
operatively decreased from 30% to 11% with use of the order
form. The use of an order form for all inpatient antimicrobial
orders in an 800-bed hospital that required clinical indication,
as well as a defined duration before order renewal, led to a 30%
decrease in antibiotic courses and a 2% decrease in the hospital
pharmacy budget for parenteral antibiotics over a 25-month
period, during which time most hospitals were experiencing an
increase in expenditures [101]. Use of an antibiotic order form
for vancomycin did not improve appropriate use of vancomycin
in a pediatric hospital [104]. Automatic stop orders should not
replace clinical judgment, and renewal requirements must be
clearly communicated to providers to avoid inappropriate treat-
ment interruptions.
Recommendation
• Antimicrobial order forms can be an effective component
of antimicrobial stewardship (B-II) and can facilitate im-
plementation of practice guidelines.
Combination therapy: prevention of resistance versus re-
dundant antimicrobial coverage. The rationale for combi-
nation antimicrobial therapy includes broad-spectrum empir-
ical therapy for serious infections, improved clinical outcomes,
and the prevention of resistance. Inadequate initial antimicro-
bial therapy was found to be an independent risk factor for
mortality in nonurinary infections due to extended-spectrum
b-lactamase–producing Escherichia coli and Klebsiella species
[105]. Similarly, inadequate early antimicrobial coverage has
been associated with increased mortality in patients with micro-
biologically confirmed severe sepsis (39% vs. 24%) [106] and
critically ill ICU patients (42% vs. 18%) [55], leading to in-
corporation of empirical combination therapy for late-onset
VAP in the recent IDSA–American Thoracic Society guidelines
[107]. These studies highlight the need to assess risk factors for
multidrug-resistant pathogens when selecting empirical anti-
microbial therapy for critically ill patients.
However, in many situations, combination therapy is re-
dundant and unnecessary. Evidence supporting the role of com-
bination antimicrobial therapy for the prevention of resistance
is limited to those situations in which there is a high organism
load combined with a high frequency of mutational resistance
during therapy. Classic examples are tuberculosis or HIV in-
fection. There is often debate about the role of combination
therapy in serious infections due to gram-negative organisms,
such as Pseudomonas species, but clear evidence supporting a
clinical benefit or resistance benefit is lacking [108–118]. A
meta-analysis of randomized, controlled trials comparing a b-
lactam plus an aminoglycoside as combination therapy with b-
lactam monotherapy for the treatment of hospitalized patients
with serious infections found no difference in the emergence
of antimicrobial resistance. In fact, b-lactam monotherapy was
associated with fewer superinfections [119].
Recommendation
• There are insufficient data to recommend the routine use
of combination therapy to prevent the emergence of resis-
tance (C-II). Combination therapy does have a role in cer-
tain clinical contexts, including use for empirical therapy
for critically ill patients at risk of infection with multidrug-
resistant pathogens, to increase the breadth of coverage and
the likelihood of adequate initial therapy (A-II).
Streamlining or de-escalation of therapy. Good steward-
ship to optimize empirical initial antimicrobial therapy may
conflict with good stewardship to promote judicious use, be-
cause continuing excessively broad therapy contributes to the
selection of antimicrobial resistant pathogens [120]. This con-
flict can be resolved when culture results become available by
streamlining or de-escalating antimicrobial therapy to more
targeted therapy that decreases antimicrobial exposure and con-
tains cost. De-escalation may also include discontinuation of
empirical antimicrobial therapy based on clinical criteria and
negative culture results as demonstrated in the management of
suspected VAP [79, 107, 121]. Review by a pharmacist and an
infectious diseases physician of 625 patients receiving combi-
nation antimicrobial therapy led to streamlining recommen-
dations in 54% of antimicrobial courses over 7 months, re-
sulting in a projected annual savings of $107,637 [122].
In another study, a computer query to mine the hospital
pharmacy database followed by targeted review by an infectious
diseases clinical pharmacist facilitated the identification of po-
tentially redundant antimicrobial combinations in 16% of pa-
tients receiving 2 antimicrobials. Even after accepting the
debatable “double gram-negative coverage,” 71% of the com-
binations were deemed to be inappropriate. Interestingly, half
of the redundancy was due to physician prescribing error,
whereas the other half was due to medication ordering and
distribution system errors. The annualized potential savings
from this intervention was estimated to be $60,000, and ∼3500
redundant inpatient antibiotic–days were avoided [123].
Recommendation
• Streamlining or de-escalation of empirical antimicrobial
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therapy on the basis of culture results and elimination of
redundant combination therapy can more effectively target
the causative pathogen, resulting in decreased antimicrobial
exposure and substantial cost savings (A-II).
Dose optimization. Optimization of antimicrobial dosing
that accounts for individual patient characteristics (e.g., age,
renal function, and weight), causative organism and site of
infection (e.g., endocarditis, meningitis, and osteomyelitis), and
pharmacokinetic and pharmacodynamic characteristics of the
drug is an important part of antimicrobial stewardship. For
instance, the bactericidal activity of b-lactams correlates with
the percentage of time that the drug concentration remains
greater than the MIC, whereas fluoroquinolones and aminog-
lycosides are concentration-dependent agents, with the ratio of
the maximum concentration to the MIC or the ratio of the
area under the curve to the MIC being important predictors
of activity. Examples of these principles in practice include
prolonged or continuous infusion of b-lactams [124], ex-
tended-interval dosing of aminoglycosides [125], and dosing
of fluoroquinolones for Streptococcus pneumoniae in commu-
nity-acquired pneumonia [126, 127] and for Pseudomonas in
HAP and VAP [107]. The use of pharmacokinetic and phar-
macodynamic principles is more likely to be in development
of antimicrobial use guidelines than in individual patients’ care.
Recommendation
• Optimization of antimicrobial dosing based on individual
patient characteristics, causative organism, site of infection,
and pharmacokinetic and pharmacodynamic characteristics
of the drug is an important part of antimicrobial steward-
ship (A-II).
Conversion from parenteral to oral therapy. Antimicrobial
therapy for patients with serious infections requiring hospital-
ization is generally initiated with parenteral therapy. Enhanced
oral bioavailability among certain antimicrobials—such as flu-
oroquinolones, oxazolidinones, metronidazole, clindamycin,
trimethoprim-sulfamethoxazole, fluconazole, and voricona-
zole—allows conversion to oral therapy once a patient meets
defined clinical criteria. This can result in reduced length of
hospital stay, health care costs, and potential complications due
to intravenous access.
Randomized studies evaluating early transition from par-
enteral to oral therapy in the management of adults with com-
munity-acquired pneumonia have demonstrated significant re-
ductions in length of hospital stay and cost of care with no
adverse effect on clinical outcomes [128–130]. A similar de-
crease in length of hospital stay, with a 52% reduction in total
health care costs, was noted in the treatment of lower respi-
ratory tract infections in children, compared with historical
control subjects [131]. A pharmacist-initiated program utilizing
predetermined clinical criteria for general conversion from par-
enteral to oral therapy decreased length of hospital stay by 1.53
days, with cost savings for drug acquisition and reduced length
of hospital stay of $15,149 and $161,072, respectively, over 12
months [132].
A randomized study of oral linezolid versus intravenous van-
comycin in patients with complicated skin and soft-tissue in-
fections due to MRSA demonstrated a decreased mean length
of hospital stay of 5 days for the linezolid group [133], and a
switch from vancomycin to oral linezolid for early discharge
from the hospital resulted in an annual savings of $294,750
[134]. The use of new agents, such as linezolid, in this manner
must be done judiciously and with the direct oversight of an
antimicrobial-management program to balance concerns about
the development of resistance and added antimicrobial acqui-
sition costs.
A systematic plan for switching from parenteral to oral treat-
ment may have an added benefit of aiding in early hospital
discharge planning, if needed, to provide surge capacity during
local or national problems (e.g., epidemic influenza).
Recommendation
• A systematic plan for parenteral to oral conversion of an-
timicrobials with excellent bioavailability, when the patient’s
condition allows, can decrease length of hospital stay and
health care costs (A-I). Development of clinical criteria and
guidelines allowing conversion to use of oral agents can
facilitate implementation at the institutional level (A-III).
Computer Surveillance and Decision Support
Increased focus on medical errors and patient safety led to a
series of reports by the Institute of Medicine’s National Round-
table on Health Care Quality to emphasize the role of infor-
mation technology in the delivery of health care [135–137].
The Leapfrog Group has identified computer physician order
entry (CPOE) as 1 of the 3 most important “leaps” that or-
ganizations can take to substantially improve patient safety.
CPOE has the potential to incorporate clinical decision support
and to facilitate quality monitoring [138]. Progress to this end,
however, remains slow, with only 13% of US hospitals con-
verting to electronic medical records and 5% implementing
CPOE as of 2002 [139, 140].
The most well-described computer surveillance and decision-
support system related to antimicrobial prescribing linked to
electronic medical records is from LDS Hospital in Salt Lake
City, Utah [141]. This program presents epidemiologic infor-
mation with detailed recommendations and warnings regarding
antimicrobial regimens and courses of therapy. Even if a phy-
sician overrides the recommendation for the antimicrobial and
selects his or her own treatment plan, the computer still au-
tomatically reviews the patient’s allergies and potential drug-
drug interactions, recommending a dosage and interval based
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on the patient’s renal and hepatic function. A prospective study
of the use of this program in an ICU demonstrated significant
reductions in orders for drugs to which the patients had re-
ported allergies, excess drug dosages based on renal function,
adverse drug events, antimicrobial-susceptibility mismatches,
antimicrobial costs, and length of hospital stay [142]. Imple-
mentation of a computer-assisted antibiotic-dose monitor
throughout the same hospital over a 12-month period identified
1974 (44%) of 4483 patients receiving excessive antimicrobial
dosages (based on renal function), leading to more-appropriate
dosing and fewer adverse drug events [143]. Incorporation of
practice guidelines into the system increased the percentage of
surgical patients who received their preoperative prophylactic
antimicrobials within 2 h of incision from 40% to 99.1%
[144, 145].
In addition to improving antimicrobial use and care of the
individual patient, their system has facilitated the electronic
surveillance of hospital-acquired infections and adverse drug
events. Computer surveillance identified 90% of confirmed
nosocomial infections, compared with 76% of such infections
identified by manual surveillance, allowing infection control
practitioners to reduce the time required for such activities by
65% [146]. Automated surveillance of 36,653 patients over 18
months using defined triggers identified 731 adverse drug
events, whereas only 9 were reported through traditional vol-
untary incident reports [147].
This computer decision-support system was adapted for use
in pediatric patients by Mullett et al. [148], and its effect was
evaluated in a quasi experimental study. Dosing guidelines were
adjusted for pediatric and neonatal populations, to ensure that
treatment recommendations were appropriate for infections
common in the pediatric population (e.g., bacterial meningitis),
local antimicrobial resistance patterns (e.g., the prevalence of
S. pneumoniae with reduced susceptibility to penicillin), special
populations (e.g., children with cystic fibrosis), and children
with renal insufficiency. Comparing a 6-month period after
implementation (intervention period) with the prior 6 months
(baseline period), the decision-support system was associated
with a 59% decrease in the rate of pharmacy interventions for
erroneous drug doses and 36% and 28% decreases in the rates
of subtherapeutic and excessive antimicrobial dosing days, re-
spectively. There was a 9% decrease in the cost of antimicrobial
agents during the intervention period. The frequency of adverse
drug events and antimicrobial-bacterial susceptibility mis-
matches were not significantly different during the intervention
period—a finding likely attributable to the low frequency of
these events in the baseline period. Clinicians using the system
reported that they felt that the program improved their selec-
tion of antimicrobial agents, increased their awareness of im-
pairments in renal function that affected drug dosing, and re-
duced the likelihood of adverse drug events. The lead
investigator has subsequently developed a separate decision-
support system for treatment of bloodstream infection in hos-
pitalized children, although the system has not yet been eval-
uated prospectively [149].
A randomized study incorporating guidelines for vanco-
mycin use into a hospital’s CPOE at the time of initial ordering
and after 72 h of therapy led to 32% fewer vancomycin orders
and a 36% reduction in the duration of vancomycin therapy.
This resulted in a projected savings of $90,000 [150]. Simply
adding antimicrobial cost information to antimicrobial sus-
ceptibility data resulted in decreased average monthly antimi-
crobial expenditures by $7636 (17%) in another hospital [151].
Despite these initial promising studies, matching the linear
technology of CPOE with complex clinical management that
can be subjective, interpretive, and reactive has been a challenge
at other institutions [152]. Implementation of CPOE at a 750-
bed teaching hospital to reduce medical errors was actually
found to frequently facilitate medication errors [140]. Errors
included inappropriate dose selection, double-dosing caused by
separate order and discontinuation functions, and gaps in an-
timicrobial therapy resulting from automatic discontinuation
orders. In large part, these errors reflected the difficulty of
implementation rather than the concept of CPOE.
The Veterans Administration health care system has been a
leader in the use of an electronic medical records and CPOE.
Despite being a model for implementing CPOE, one Veterans
Administration hospital found a continuing high rate of adverse
drug events in the absence of decision support for drug selec-
tion, dosing, and monitoring [153]. Twenty-six percent of hos-
pital admissions were associated with at least 1 adverse drug
event, with medication errors contributing to 27% of these
adverse events.
The lofty goal of merging the electronic records with CPOE
and clinical decision support to optimize antimicrobial use is
currently not attainable for most institutions on the basis of
current technology. Depending on available resources, however,
automated targeting of interventions to facilitate antimicrobial
stewardship can be obtained through varying levels of com-
plexity. Such targeting may include using pharmacy records to
identify patients who are receiving broad-spectrum or expensive
antimicrobials, use of simple computer programs that merge
hospital pharmacy and microbiology databases, and use of
more-complex, commercially available software to identify an-
timicrobial interventions.
Recommendations
• Health care information technology in the form of electronic
medical records (A-III), CPOE (B-II), and clinical decision
support (B-II) can improve antimicrobial decisions through
the incorporation of data on patient-specific microbiology
cultures and susceptibilities, hepatic and renal function,
drug-drug interactions, allergies, and cost. However, im-
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plementation of these features has been slow, and confor-
mation of the technology to the clinical environment re-
mains a challenge.
• Computer-based surveillance can facilitate good steward-
ship by more efficient targeting of antimicrobial interven-
tions, tracking of antimicrobial resistance patterns, and
identification of nosocomial infections and adverse drug
events (B-II).
Microbiology Laboratory
The clinical microbiology laboratory plays a critical role in the
timely identification of microbial pathogens and the perfor-
mance of susceptibility testing [154, 155]. Susceptibility testing
and reporting should be based on the guidelines developed by
the Clinical and Laboratory Standards Institute (CLSI; formerly
the NCCLS) [156]. Prioritization of tested antimicrobials and
selective reporting of susceptibility profiles (e.g., not routinely
reporting susceptibility of S. aureus to rifampin to prevent in-
advertent monotherapy with rifampin) can aid in the prudent
use of antimicrobials and direct appropriate therapy based on
local guidelines. The advance of molecular diagnostics allows
the identification of difficult-to-culture pathogens, potentially
avoiding the need for extended courses of broad-spectrum em-
pirical therapy.
In addition to routine susceptibility testing, the clinical mi-
crobiology laboratory should be actively involved in resistance
surveillance. Local antibiograms with pathogen-specific sus-
ceptibility data should be updated at least annually, to optimize
expert-based recommendations for empirical therapy [157].
Computerized surveillance can facilitate more-frequent mon-
itoring of antimicrobial resistance trends, as well as provide
ICU- or ward-specific data and inpatient versus outpatient data,
recognizing that different parts of a health care institution can
have very different patterns of antimicrobial use and resistance
[157]. Besides qualitative determination of antimicrobial resis-
tance or susceptibility, periodic review of MICs or zone di-
ameters in disk-diffusion techniques can detect early trends of
emerging resistance, even within the “susceptibility” cut-offs.
Kirby-Bauer disk-diffusion methods can also be used to per-
form the D test for inducible clindamycin resistance for S.
aureus [158], as well as provide quick screenings for extended-
spectrum b-lactamase– and AmpC b-lactamase–containing or-
ganisms. Finally, the laboratory is an important partner with
infection control in the identification and molecular epide-
miologic investigation of local outbreaks of infection. The de-
velopment of rapid resistance testing will facilitate the surveil-
lance of organisms such as MRSA and VRE, allowing the more
rapid implementation of infection control measures to prevent
secondary spread [159, 160]. Clonal characterization of resis-
tant strains through molecular typing can help focus appro-
priate interventions, leading to a reduction in nosocomial in-
fections with associated cost savings [161]. If antimicrobial
resistance is due to a clonal outbreak, antimicrobial interven-
tions may be of limited value, compared with infection control
interventions. If resistant strains are diverse, antimicrobial in-
terventions may be required.
Recommendation
• The clinical microbiology laboratory plays a critical role in
antimicrobial stewardship by providing patient-specific cul-
ture and susceptibility data to optimize individual antimi-
crobial management and by assisting infection control ef-
forts in the surveillance of resistant organisms and in the
molecular epidemiologic investigation of outbreaks (A-III).
Monitoring of Process and Outcome Measurements
In conjunction with developing local strategies for improving
antimicrobial stewardship, programs must establish process and
outcome measures to determine the impact of antimicrobial
stewardship on antimicrobial use and resistance patterns. Fur-
thermore, health care systems must invest in data systems to
allow the evaluation of antimicrobial stewardship as a routine
measure of quality improvement [162]. With antimicrobial ste-
wardship, the “process goal” is often to change use of a specific
antimicrobial or class of antimicrobials. The related “process
measure” for this goal would determine the degree to which
the intervention to change the use of an antimicrobial or class
of antimicrobials has been successfully implemented, compared
with baseline levels. The desired “outcome goal” of these pro-
cess changes is to reduce or prevent resistance or other unin-
tended consequences of antimicrobial use. “Outcome mea-
surements” define the degree to which these outcomes are
achieved, such as reduced antimicrobial resistance, adverse drug
events, and cost, as well as unintended consequences, such as
rates of C. difficile infection and the use of nontargeted anti-
microbials as a result of the process change.
Antimicrobial use data based on pharmacy expenditure or
dispensing reports often do not account for drug wastage, un-
used doses returned to pharmacy, or fluctuations in institu-
tional price structures and discounts [163]. Drug use data can
be standardized using the defined daily dose, calculated as the
total number of grams of an antimicrobial agent used divided
by the number of grams in an average adult daily dose of the
agent [164]. The World Health Organization publishes defined
daily dose values for nearly all antimicrobials (http://
www.whocc.no/atcddd/). The use of defined daily doses is rec-
ommended so that hospitals may compare their antimicrobial
use with that of other similar hospitals, recognizing the chal-
lenges of interhospital comparisons and the potential need for
“risk adjustment.” However, in populations with renal com-
promise (e.g., the elderly population) and for drugs that require
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renal dose adjustment, the defined daily dose may be less ac-
curate than measures of antimicrobial-days of therapy [165].
Recommendation
• Both process measures (did the intervention result in the
desired change in antimicrobial use?) and outcome mea-
sures (did the process implemented reduce or prevent re-
sistance or other unintended consequences of antimicrobial
use?) are useful in determining the impact of antimicrobial
stewardship on antimicrobial use and resistance patterns (B-
III).
Comprehensive Multidisciplinary Antimicrobial Management
Programs
Through the previous review of individual interventions di-
rected at improving antimicrobial use, it is clear that effective
antimicrobial stewardship requires a multidisciplinary team ap-
proach that incorporates many of these elements simulta-
neously. The core members of a comprehensive antimicrobial
management program include an infectious diseases physician
and a clinical pharmacist with infectious diseases training, with
the inclusion of infection control professionals, the hospital
epidemiologist, a clinical microbiologist, and an information
system specialist, when possible [166–174]. The latter is critical
for linking the patient’s medical record to the pharmacy and
microbiology databases, to identify interventions and to per-
form surveillance activities. Program personnel should be in-
cluded as active members on the hospital infection control and
pharmacy and therapeutics committees or their equivalents.
Central to an effective program is a proactive strategy in-
corporating prospective audit with direct intervention and feed-
back to the provider and/or preauthorization requirements for
antimicrobial use. On the basis of an understanding of local
antimicrobial use and resistance problems and of available re-
sources that may differ depending on the size of the institution,
the core active strategies may be supplemented by education,
guidelines and clinical pathways, antimicrobial order forms,
adequate empirical therapy followed by de-escalation based on
culture results, dose optimization, and a systematic plan for
conversion from parenteral to oral therapy. Consensus building
with the support of administration and local providers is es-
sential, with the focus on collaborating in the safety and care
of their patients rather than a policing role. Although reports
describing the clinical and economic impacts of multidisci-
plinary antimicrobial management programs are limited to sin-
gle-center longitudinal studies, they consistently demonstrate
a decrease in antimicrobial use (22%–36%) and annual savings
of $200,000–$900,000, which more than pays for the program
in both larger academic hospitals [2, 3, 5, 7, 8, 69] and smaller
community hospitals [4, 6]. Quantifying a long-term impact
on antimicrobial resistance has been more challenging, and
further studies are needed to determine the optimal processes
by which the goals of improved clinical outcomes and con-
tainment of antimicrobial resistance can be achieved. However,
given the strong association between antimicrobial use and an-
timicrobial resistance (table 2), improving antimicrobial ste-
wardship is an important first step.
RESEARCH PRIORITIES AND FUTURE
DIRECTIONS
Because of the limited number of randomized clinical studies
addressing antimicrobial stewardship strategies, many of the
recommendations in this guideline are based on level III evi-
dence. Further research and evaluation through appropriately
conducted clinical trials are necessary to determine the best
strategies for the prevention and containment of antimicrobial
resistance. Recommended topics for investigation are as follows:
1. Antimicrobial cycling at the patient, unit, and insti-
tutional level to determine whether cycling is effective and, if
so, the optimal antimicrobials to be cycled, the optimal du-
ration of the cycles, and the preferred order in which agents
should be cycled.
2. Clinical validation of mathematical models suggesting
that heterogeneous antimicrobial use slows the spread of
resistance.
3. The long-term impact of formulary restriction and
preauthorization requirements on antimicrobial use and
resistance.
4. Evaluation of “bundled” approaches that incorporate
many or all of the most effective strategies.
5. Examination of the effectiveness of these strategies in
more detail in subpopulations of hospitalized patients, includ-
ing neonates, infants, and children; elderly patients; and severely
immunocompromised patients.
6. The ability of antimicrobials to cause “collateral dam-
age” or unintended ecological resistance, to focus interventions.
7. The incremental role of antimicrobial stewardship
combined with infection control practices, such as hand hy-
giene and isolation, designed to prevent secondary spread of
resistant organisms.
8. Understanding the resistance gene pool through mo-
lecular epidemiology, to determine the relative impact of an-
timicrobial stewardship and infection control practices on spe-
cific resistant bacteria, to tailor an approach to local resistance
issues.
9. Development and validation of automated surveillance
strategies for nosocomial infections and real-time monitoring
of resistance trends.
10. Development of decision-support systems incorpo-
rating antimicrobial stewardship into CPOE.
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11. Development and cost-effectiveness of more rapid and
sensitive diagnostic tests, to identify patients with bacterial ver-
sus viral infections and to identify resistant bacterial organisms
earlier.
12. Strategies to stimulate research and development of
novel antimicrobials as outlined in the IDSA “Bad Bugs, No
Drugs” campaign.
13. Education and training of infectious diseases fellows
and pharmacists in the area of antimicrobial stewardship, in-
cluding program implementation and management.
14. The influence of pharmaceutical industry and repre-
sentatives on antimicrobial prescribing within the health care
setting and effective strategies to counteract inappropriate
detailing.
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